COLUMBIA, Md.--(BUSINESS WIRE)--CELSION CORPORATION (AMEX:CLN) today reported that on May 16, 2007 at the joint meeting of the World Congress on Interventional Oncology and the Society for Thermal Medicine, in Washington DC, Dr. Zeljko Vujaskovic, Associate Clinical Professor at Duke University, presented early data from a Phase I dose escalation and safety study using ThermoDox to treat patients with recurrent breast cancer on the chest wall. He reported that at low doses (three patients at 20mg/m2 and three patients at 30mg/m2), after only two cycles of a six cycle regimen, all six patients showed early signs of clinically meaningful activity, one patient had a complete response in the treated area, two patients had a partial response and three patients had stable disease following treatment.
